Zhangjiang Group And Sundia MediTech To Promote New Pharmaceutical R&D Outsourcing Model
This article was originally published in PharmAsia News
Executive Summary
Zhangjiang Group and Sundia MediTech have signed a collaboration agreement on new drug R&D outsourcing. The latter will integrate CRO resources to provide full-stop services for new drug development. Zhangjiang will be the first in China to implement the intellectual property plus CRO plus venture capital model to target new drug development in the country. Scheduled for completion within four years, the platform will screen and support promising class I new drug innovation projects with IP rights, as well as establish a pool of independent experts and funds to form a full drug development chain. The fresh approach will accelerate the local rate of securing authentication from the College of American Pathologists, a prerequisite for entering the global CRO market. (Click here for more - Chinese language)